Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Mydecine Innovations Group ( (TSE:MYCO) ) is now available.
Mydecine Innovations Group has announced an update regarding the delay in filing its annual financial statements for the fiscal year ended December 31, 2024. The company expects to complete these filings by June 30, 2025, and will follow with its interim financial statements shortly after. During this period, a management cease trade order restricts trading by the company’s CEO and CFO, although public trading of shares continues. The company remains committed to fulfilling regulatory requirements and will provide updates as necessary.
More about Mydecine Innovations Group
Mydecine Innovations Group Inc. is a biotechnology company focused on developing innovative medications and therapies to address mental health disorders such as nicotine addiction and PTSD. The company combines advanced technology with drug discovery and development infrastructure, aiming to create breakthrough treatment solutions in areas with significant unmet needs. Mydecine collaborates with leading specialists to accelerate the development of safer and more effective treatments, with a focus on next-generation psychedelic medicine.
Average Trading Volume: 49,791
Technical Sentiment Signal: Sell
Current Market Cap: C$308.8K
See more data about MYCO stock on TipRanks’ Stock Analysis page.